⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MLYS News
Mineralys Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
MLYS
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
globenewswire.com
MLYS
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
globenewswire.com
MLYS
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
prnewswire.com
MLYS
PROK
IRON
REGN
AMGN
MAZE
LLY
JNJ
LXRX
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MLYS
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MLYS
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
globenewswire.com
MLYS
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
globenewswire.com
MLYS
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MLYS
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
MLYS